40. McKeith I.G. Dementia with Lewy bodies: a clinical overview. Dementia CRC Press., 2017. c. 739–749.
41. Thomas A.J., Taylor J.P., McKeith I. et al. Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study. Int J Geriatr Psychiatry 2018; №33(10): 1293–1304.
42. Wenning G.K., Geser F., Krismer F. et al. The natural history of multiple system atrophy: A prospective European cohort study. Lancet Neurol 2013; №12 (3):264-274.
43. Low P.A., Reich S.G., Jankovic J. et al. Natural history of multiple system atrophy in the USA: A prospective cohort study. Lancet Neurol 2015; №14 (7):710-719.
44. Nath U., Ben-Shlomo Y., Thomson R.G. et al. Clinical features and natural history of progressive supranuclear palsy: A clinical cohort study. Neurology 2003; №60 (6): 910-916.
45. Glasmacher S.A., Leigh P.N., Saha R.A. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; №88 (5): 402-411.
46. Papapetropoulos S., Singer C., McCorquodale D. et al. Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 2005; №11 (7): 459-463.
47. Postuma R.B. et al. MDS clinical diagnostic criteria for Parkinson’s disease // Mov. Disord. 2015. Vol. 30, № 12. P. 1591–1601.
48. Руководство по диагностике и лечению болезни Паркинсона / под ред. Иллариошкина С.Н., Левина О.С. Москва: ООО "ИПК Парето-Принт, 2017. 336 с.
49. Houlden H. et al. Multiple system atrophy: Genetic risks and alpha-synuclein mutations // F1000Research. 2017. Vol. 6, № 0. P. 1–10.
50. Papay K. et al. Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: Validity and variability // Parkinsonism Relat. Disord. 2011. Vol. 17, № 3. P. 153–155.
51. Pluim C.F. et al. Changes in Self- and Informant-Reported Frontal Behaviors in Parkinson’s Disease: A Longitudinal Study // J. Geriatr. Psychiatry Neurol. 2020. P. 089198872096425.
52. Berardelli A. et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease // Eur. J. Neurol. 2013. Vol. 20, № 1. P. 16–34.
53. Abraham D.S. et al. Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson’s Disease // Am. J. Geriatr. Psychiatry. 2021. Vol. 29, № 1. P. 35–47.
54. Baiano C. et al. Prevalence and Clinical Aspects of Mild Cognitive Impairment in Parkinson’s Disease: A Meta‐Analysis // Mov. Disord. 2020. Vol. 35, № 1. P. 45–54.
55. Koerts J. et al. Working capacity of patients with Parkinson’s disease – A systematic review // Parkinsonism Relat. Disord. 2016. Vol. 27. P. 9–24.
56. Hariz G.-M., Forsgren L. Activities of daily living and quality of life in persons with newly diagnosed Parkinson’s disease according to subtype of disease, and in comparison to healthy controls // Acta Neurol. Scand. 2011. Vol. 123, № 1. P. 20–27.
57. Zhao N. et al. Quality of life in Parkinson’s disease: A systematic review and meta‐analysis of comparative studies // CNS Neurosci. Ther. 2021. Vol. 27, № 3. P. 270–279.
58. Wang X. et al. Comorbidity burden of patients with Parkinson’s disease and Parkinsonism between 2003 and 2012: A multicentre, nationwide, retrospective study in China // Sci. Rep. 2017. Vol. 7, № 1. P. 1671.
59. Santiago J.A., Bottero V., Potashkin J.A. Biological and Clinical Implications of Comorbidities in Parkinson’s Disease // Front. Aging Neurosci. 2017. Vol. 9.
60. Bajaj S. et al. Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis // PLoS One / ed. Kassubek J. 2017. Vol. 12, № 12. P. e0189897.
61. Zhang K. et al. Diagnostic validity of magnetic resonance parkinsonism index in differentiating patients with progressive supranuclear palsy from patients with Parkinson’s disease // Parkinsonism Relat. Disord. 2019. Vol. 66. P. 176–181.
62. Schwarz S.T. et al. The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinson’s Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T // PLoS One / ed. Bush A.I. 2014. Vol. 9, № 4. P. e93814.
63. Shafieesabet A. et al. Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson’s disease: A meta-analysis // Parkinsonism Relat. Disord. 2017. Vol. 42. P. 1–11.
64. Zhou H.Y. et al. The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy // Transl. Neurodegener. Translational Neurodegeneration, 2018. Vol. 7, № 1. P. 1–7.
65. Heiss W.-D., Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson’s disease // Eur. J. Neurol. 2004. Vol. 11, № 1. P. 5–12.
66. Booth T.C. et al. The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1 // Am. J. Neuroradiol. 2015. Vol. 36, № 2. P. 229–235.
67. Clarke C.E., Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease // J. Neurol. Neurosurg. & Psychiatry. 2000. Vol. 69, № 5. P. 590 LP – 594.
68. Li K. et al. Diagnostic accuracy of REM sleep behaviour disorder screening questionnaire: a meta-analysis // Neurol. Sci. 2017. Vol. 38, № 6. P. 1039–1046.
69. Chahine L.M., Amara A.W., Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015 // Sleep Med. Rev. 2017. Vol. 35. P. 33–50.